Assignee
GTX INC
US·28 granted patents·7 pending applications·268 citations·filing 2002–2019
Top patents by PatentIndex Score
35 records- 0197US9150501B2Solid forms of selective androgen receptor modulatorsGTX INC·Filed 2013·Granted Oct 6, 2015·19 cites·8 claims
- 0297US8003689B2Metabolites of selective androgen receptor modulators and methods of use thereofGTX INC·Filed 2009·Granted Aug 23, 2011·48 cites·2 claims
- 0396US10441570B2Selective androgen receptor degrader (SARD) Ligands and methods of use thereofGTX INC·Filed 2018·Granted Oct 15, 2019·12 cites·66 claims
- 0496US10093613B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2017·Granted Oct 9, 2018·9 cites·10 claims
- 0596US9814698B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2016·Granted Nov 14, 2017·17 cites·47 claims
- 0695US10035763B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2016·Granted Jul 31, 2018·15 cites·56 claims
- 0795US10017471B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2016·Granted Jul 10, 2018·15 cites·45 claims
- 0895US9834507B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2016·Granted Dec 5, 2017·13 cites·41 claims
- 0992US9447049B2Compounds for treatment of cancerGTX INC·Filed 2012·Granted Sep 20, 2016·12 cites·18 claims
- 1092US6899888B2Prevention and treatment of androgen-deprivation induced osteoporosisGTX INC·Filed 2002·Granted May 31, 2005·52 cites·63 claims
- 1191US9815776B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2016·Granted Nov 14, 2017·13 cites·56 claims
- 1290US10258596B2Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)GTX INC·Filed 2016·Granted Apr 16, 2019·4 cites·4 claims
- 1389US10597354B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2018·Granted Mar 24, 2020·7 cites·20 claims
- 1487US9744149B2Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)GTX INC·Filed 2015·Granted Aug 29, 2017·3 cites·12 claims
- 1585US9969683B2Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)GTX INC·Filed 2013·Granted May 15, 2018·3 cites·9 claims
- 1685US9624161B2Estrogen receptor ligands and methods of use thereofGTX INC·Filed 2014·Granted Apr 18, 2017·4 cites·15 claims
- 1784US10849873B2Non-invasive method of evaluating breast cancers for selective androgen receptor modulator (SARM) therapyGTX INC·Filed 2019·Granted Dec 1, 2020·1 cites·8 claims
- 1884US9622992B2Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)GTX INC·Filed 2014·Granted Apr 18, 2017·3 cites·29 claims
- 1978US10314807B2Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)GTX INC·Filed 2016·Granted Jun 11, 2019·1 cites·5 claims
- 2077US7595402B2Prodrugs of selective androgen receptor modulators and methods of use thereofGTX INC·Filed 2004·Granted Sep 29, 2009·9 cites·11 claims
- 2175US9051267B2Estrogen receptor ligands and methods of use thereofGTX INC·Filed 2013·Granted Jun 9, 2015·2 cites·10 claims
- 2274US9604916B2Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)GTX INC·Filed 2013·Granted Mar 28, 2017·2 cites·14 claims
- 2373US7524866B2Prevention and treatment of androgen—deprivation induced osteoporosisGTX INC·Filed 2004·Granted Apr 28, 2009·3 cites·63 claims
- 2470US10987334B2Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)GTX INC·Filed 2018·Granted Apr 27, 2021·0 cites·5 claims
- 2570US9409856B2Estrogen receptor ligands and methods of use thereofGTX INC·Filed 2015·Granted Aug 9, 2016·1 cites·48 claims
- 2664US2016128969A1Solid forms of selective androgen receptor modulatorsGTX INC·Filed 2015·Application pending·0 cites
- 2756US11090283B2Solid forms of selective androgen receptor modulatorsGTX INC·Filed 2016·Granted Aug 17, 2021·0 cites·4 claims
- 2848US2018177755A1METHODS OF TREATING UROLOGICAL DISORDERS USING SARMsGTX INC·Filed 2017·Application pending·0 cites
- 2948US2018325858A1METHODS OF TREATING UROLOGICAL DISORDERS USING SARMsGTX INC·Filed 2018·Application pending·0 cites
- 3048US2018353460A1METHODS OF TREATING UROLOGICAL DISORDERS USING SARMsGTX INC·Filed 2018·Application pending·0 cites
- 3144US9981915B2Compounds for treatment of cancerGTX INC·Filed 2015·Granted May 29, 2018·0 cites·7 claims
- 3243US9604931B2Nuclear receptor binding agentsGTX INC·Filed 2012·Granted Mar 28, 2017·0 cites·13 claims
- 3343US2016106702A1METHODS OF TREATING UROLOGICAL DISORDERS USING SARMsGTX INC·Filed 2015·Application pending·0 cites
- 3443US2013122085A1Pharmaceutical compositions of selective androgen receptor modulators and methods of use thereofGTX INC·Filed 2012·Application pending·0 cites
- 3537US2017014401A1Nuclear receptor binding agentsGTX INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when GTX INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →